PMID- 27207154
OWN - NLM
STAT- MEDLINE
DCOM- 20171017
LR  - 20190318
IS  - 1879-0046 (Electronic)
IS  - 0376-8716 (Linking)
VI  - 164
DP  - 2016 Jul 1
TI  - Benzylpiperazine: "A messy drug".
PG  - 1-7
LID - S0376-8716(16)30037-0 [pii]
LID - 10.1016/j.drugalcdep.2016.04.010 [doi]
AB  - Designer drugs are synthetic structural analogues/congeners of controlled 
      substances with slightly modified chemical structures intended to mimic the 
      pharmacological effects of known drugs of abuse so as to evade drug 
      classification. Benzylpiperazine (BZP), a piperazine derivative, elevates 
      synaptic dopamine and serotonin levels producing stimulatory and hallucinogenic 
      effects, respectively, similar to the well-known drug of abuse, 
      methylenedioxymethamphetamine (MDMA). Furthermore, BZP augments the release of 
      norepinephrine by inhibiting presynaptic autoreceptors, therefore, BZP is a 
      "messy drug" due to its multifaceted regulation of synaptic monoamine 
      neurotransmitters. Initially, pharmaceutical companies used BZP as a therapeutic 
      drug for the treatment of various disease states, but due to its 
      contraindications and abuse potential it was withdrawn from the market. BZP 
      imparts predominately sympathomimetic effects accompanied by serious 
      cardiovascular implications. Addictive properties of BZP include behavioral 
      sensitization, cross sensitization, conditioned place preference and repeated 
      self-administration. Additional testing of piperazine derived drugs is needed due 
      to a scarcity of toxicological data and widely abuse worldwide.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Katz, D P
AU  - Katz DP
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      dzk0027@auburn.edu.
FAU - Deruiter, J
AU  - Deruiter J
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      deruija@auburn.edu.
FAU - Bhattacharya, D
AU  - Bhattacharya D
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      dzb0023@auburn.edu.
FAU - Ahuja, M
AU  - Ahuja M
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      mza0016@auburn.edu.
FAU - Bhattacharya, S
AU  - Bhattacharya S
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      szb0050@auburn.edu.
FAU - Clark, C R
AU  - Clark CR
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      clarkcr@auburn.edu.
FAU - Suppiramaniam, V
AU  - Suppiramaniam V
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      suppivd@auburn.edu.
FAU - Dhanasekaran, M
AU  - Dhanasekaran M
AD  - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn 
      University, Auburn, AL 36849, United States. Electronic address: 
      dhanamu@auburn.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160506
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - 0 (Designer Drugs)
RN  - 0 (Hallucinogens)
RN  - 0 (Piperazines)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - 333DO1RDJY (Serotonin)
RN  - 3UG152ZU0E (1-benzylpiperazine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Contraindications
MH  - Designer Drugs/*pharmacology
MH  - Dopamine/metabolism
MH  - Hallucinogens/*pharmacology
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - Norepinephrine/metabolism
MH  - Piperazines/*pharmacology
MH  - Serotonin/metabolism
MH  - Substance-Related Disorders/etiology
MH  - Vesicular Monoamine Transport Proteins/drug effects
OTO - NOTNLM
OT  - *Benzylpiperazine
OT  - *Designer drugs
OT  - *Monoaminergic toxicity
OT  - *Piperazine derivatives
OT  - *Substances of abuse
OT  - *Toxicokinetics
EDAT- 2016/05/22 06:00
MHDA- 2017/10/19 06:00
CRDT- 2016/05/22 06:00
PHST- 2015/10/08 00:00 [received]
PHST- 2016/04/01 00:00 [revised]
PHST- 2016/04/03 00:00 [accepted]
PHST- 2016/05/22 06:00 [entrez]
PHST- 2016/05/22 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
AID - S0376-8716(16)30037-0 [pii]
AID - 10.1016/j.drugalcdep.2016.04.010 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2016 Jul 1;164:1-7. doi: 10.1016/j.drugalcdep.2016.04.010. 
      Epub 2016 May 6.